The event will provide a solid base for networking within the biotech sector and aimed at raising awareness of the Commercial Outsourcing landscape related to Pharmaceutical Product Discovery, Development and Manufacture.
This is an ever changing environment and as such companies operating in this space need guidance, assistance and strong relationships with partner organisations in order to operate as effectively as possible.
The UK Chemical and Science Industries have changed considerably over the past few decades and will continue to change and as a consequence outsourcing has become the Industry norm for large pharma to work effectively and streamline their business.
Biotech companies do not have the resource or the money to develop their own products effectively and like major pharma will look for cost effective solutions often in the Asia-Pacific market to meet their needs.
China is growing in dominance but does such rapid growth represent unforeseen challenges? India is well placed to serve both quality and meet timelines but price is increasing with GDP. Where is the Industry moving? What effect does this have on the UK Science Industry and Economy? What is essential in product development? How do you identify the right partner in such a competitive landscape? Is relationship the key factor to working together? How can we learn from the major pharma model?
Aims
Speakers
Paul Madeley - Managing Director, Synth-ISIS Ltd
V Venkatanarayan - Sr Director, Formulation Technology Manager, Dr Reddy's
John Knight- Scientific Director, Scientific Update
Andrew McElroy- CEO, The Research Network
Harshad Patel - Project Leader, Pulmagen Therapeutics Ltd.
Gavin Bennet - Associate Director, Cellzome Ltd.
This is an ever changing environment and as such companies operating in this space need guidance, assistance and strong relationships with partner organisations in order to operate as effectively as possible.
The UK Chemical and Science Industries have changed considerably over the past few decades and will continue to change and as a consequence outsourcing has become the Industry norm for large pharma to work effectively and streamline their business.
Biotech companies do not have the resource or the money to develop their own products effectively and like major pharma will look for cost effective solutions often in the Asia-Pacific market to meet their needs.
China is growing in dominance but does such rapid growth represent unforeseen challenges? India is well placed to serve both quality and meet timelines but price is increasing with GDP. Where is the Industry moving? What effect does this have on the UK Science Industry and Economy? What is essential in product development? How do you identify the right partner in such a competitive landscape? Is relationship the key factor to working together? How can we learn from the major pharma model?
Aims
- learn about the Pharmaceutical Product Development process, areas that are more viable to outsource, strategies for reducing risk etc.
- hear other companies experience in this area, large pharma versus small biotech
- network effectively and build contacts with professional bodies and support organisations
Speakers
Paul Madeley - Managing Director, Synth-ISIS Ltd
V Venkatanarayan - Sr Director, Formulation Technology Manager, Dr Reddy's
John Knight- Scientific Director, Scientific Update
Andrew McElroy- CEO, The Research Network
Harshad Patel - Project Leader, Pulmagen Therapeutics Ltd.
Gavin Bennet - Associate Director, Cellzome Ltd.
